Xel Herbaceuticals

Xel Herbaceuticals was a biopharmaceutical company dedicated to enhancing the delivery and efficacy of established therapeutic agents through its proprietary "Xel" platform. Based in Salt Lake City, the company specialized in developing oral versions of chemotherapy drugs that are traditionally administered via intravenous infusion. Its lead product candidates, including Xel-101 (oral docetaxel) and Xel-001 (oral paclitaxel), were designed to improve patient quality of life by enabling at-home administration and potentially reducing systemic toxicity. The company utilized the FDA's 505(b)(2) regulatory pathway to accelerate the development of these reformulated treatments. Although the company reached clinical-stage testing for its lead programs, it is no longer active.